{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:40:29Z","timestamp":1773711629115,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serosurveillance helps establish reopening guidelines and determine the immunity levels in different populations to reach herd immunity. Then, there is an urgent need to estimate seroprevalence population wide. In Mexico, information about COVID-19 cases and related deaths is scarce. Also, there is no official serosurveillance, limiting our knowledge of the impact of the SARS-CoV-2 pandemic. Here, we report the prevalence of anti-SARS-CoV-2 antibodies in 522,690 unvaccinated people from July 5th to December 31st, 2020. The overall seroprevalence was 32.8% and highest in adults aged 30\u201339\u00a0years (38.5%) than people under 20\u00a0years (33.0%) or older (28.9%). Moreover, in a cohort of 1655 individuals confirmed COVID-19 by PCR, we found that symptomatic people (HR\u2009=\u20092.56) increased seroconversion than presymptomatic. Also, we identified that the most discriminative symptoms for COVID-19 that could predict seroconversion were anosmia and ageusia (HR\u2009=\u20091.70), fever, myalgia\/arthralgia, and cough (HR\u2009=\u20091.75). Finally, we found that obese people had lower seroconversion (HR\u2009=\u20090.53) than healthy people, but the opposite happens in diabetic people (HR\u2009=\u20091.39). These findings reveal that around one-third of Mexican outpatients had anti-SARS-CoV-2 antibodies before vaccination. Also, some symptoms improve empirically COVID-19 diagnosis and seroconversion. This information could help fine-tune vaccination schemes and the reopening and back-to-work algorithms.<\/jats:p>","DOI":"10.1038\/s41598-022-09395-3","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:05:16Z","timestamp":1648519516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico"],"prefix":"10.1038","volume":"12","author":[{"given":"Miguel A.","family":"Fern\u00e1ndez-Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Luna-Ruiz Esparza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-9528","authenticated-orcid":false,"given":"Abraham","family":"Campos-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Y.","family":"Calva-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Moreno-Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fela","family":"Mendlovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Plett-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-4223","authenticated-orcid":false,"given":"Jonathan","family":"Alc\u00e1ntar-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"9395_CR1","doi-asserted-by":"publisher","first-page":"101406","DOI":"10.1016\/j.isci.2020.101406","volume":"23","author":"T Kilic","year":"2020","unstructured":"Kilic, T., Weissleder, R. & Lee, H. Molecular and immunological diagnostic tests of COVID-19: Current status and challenges. iScience 23, 101406. https:\/\/doi.org\/10.1016\/j.isci.2020.101406 (2020).","journal-title":"iScience"},{"key":"9395_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1706","author":"A Pekosz","year":"2021","unstructured":"Pekosz, A. et al. Antigen-based testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1706 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"9395_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","volume":"6","author":"LJ Carter","year":"2020","unstructured":"Carter, L. J. et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent. Sci. 6, 591\u2013605. https:\/\/doi.org\/10.1021\/acscentsci.0c00501 (2020).","journal-title":"ACS Cent. Sci."},{"key":"9395_CR4","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3201\/eid1310.070576","volume":"13","author":"LP Wu","year":"2007","unstructured":"Wu, L. P. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 13, 1562\u20131564. https:\/\/doi.org\/10.3201\/eid1310.070576 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"9395_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3201\/eid2703.204543","volume":"27","author":"PG Choe","year":"2021","unstructured":"Choe, P. G. et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg. Infect. Dis. 27, 928\u2013931. https:\/\/doi.org\/10.3201\/eid2703.204543 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"9395_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jiph.2021.05.003","volume":"14","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic\/presymptomatic COVID-19 patients. J. Infect. Public Health 14, 845\u2013851. https:\/\/doi.org\/10.1016\/j.jiph.2021.05.003 (2021).","journal-title":"J. Infect. Public Health"},{"key":"9395_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.tim.2020.11.002","volume":"29","author":"R West","year":"2021","unstructured":"West, R., Kobokovich, A., Connell, N. & Gronvall, G. K. COVID-19 antibody tests: A valuable public health tool with limited relevance to individuals. Trends Microbiol. 29, 214\u2013223. https:\/\/doi.org\/10.1016\/j.tim.2020.11.002 (2021).","journal-title":"Trends Microbiol."},{"key":"9395_CR8","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (2020)."},{"key":"9395_CR9","unstructured":"Instituto Nacional de Estadisticas Geograf\u00eda e Informacion (INEGI). Perspectiva en cifras: COVID-19, https:\/\/www.inegi.org.mx\/investigacion\/covid\/ (2021)."},{"key":"9395_CR10","doi-asserted-by":"publisher","unstructured":"Cristina, D.-S. et al. Research Square,https:\/\/doi.org\/10.21203\/rs.3.rs-84890\/v1 (2021).","DOI":"10.21203\/rs.3.rs-84890\/v1"},{"key":"9395_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/v13071225","volume":"13","author":"N Martinez-Acu\u00f1a","year":"2021","unstructured":"Martinez-Acu\u00f1a, N. et al. Seroprevalence of anti-SARS-CoV-2 Antibodies in blood donors from Nuevo Leon State, Mexico, during 2020: A retrospective cross-sectional evaluation. Viruses 13, 1225. https:\/\/doi.org\/10.3390\/v13071225 (2021).","journal-title":"Viruses"},{"key":"9395_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/microorganisms9040850","volume":"9","author":"JE Mu\u00f1oz-Medina","year":"2021","unstructured":"Mu\u00f1oz-Medina, J. E. et al. SARS-CoV-2 IgG antibodies seroprevalence and sera neutralizing activity in MEXICO: A national cross-sectional study during 2020. Microorganisms 9, 850. https:\/\/doi.org\/10.3390\/microorganisms9040850 (2021).","journal-title":"Microorganisms"},{"key":"9395_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.19.20215558","author":"JM Remes-Troche","year":"2020","unstructured":"Remes-Troche, J. M. et al. Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico). medRxiv https:\/\/doi.org\/10.1101\/2020.10.19.20215558 (2020).","journal-title":"medRxiv"},{"key":"9395_CR14","first-page":"14","volume":"6","author":"MA Pourhoseingholi","year":"2013","unstructured":"Pourhoseingholi, M. A., Vahedi, M. & Rahimzadeh, M. Sample size calculation in medical studies. Gastroenterol. Hepatol. Bed Bench 6, 14\u201317 (2013).","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"9395_CR15","unstructured":"Direcci\u00f3n General de Epidemiologia, SSA. COVID-19 https:\/\/covid19.sinave.gob.mx\/ (Datos epidemiol\u00f3gicos, 2021)."},{"key":"9395_CR16","doi-asserted-by":"publisher","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","volume":"17","author":"D Buitrago-Garcia","year":"2020","unstructured":"Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 17, e1003346. https:\/\/doi.org\/10.1371\/journal.pmed.1003346 (2020).","journal-title":"PLoS Med."},{"key":"9395_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ijid.2020.12.086","volume":"104","author":"MA Fernandez-Rojas","year":"2021","unstructured":"Fernandez-Rojas, M. A. et al. Epidemiology of COVID-19 in Mexico: Symptomatic profiles and presymptomatic people. Int. J. Infect. Dis. 104, 572\u2013579. https:\/\/doi.org\/10.1016\/j.ijid.2020.12.086 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"9395_CR18","first-page":"10","volume-title":"GPE Discussion Paper Series","author":"OB Ahmad","year":"2000","unstructured":"Ahmad, O. B. et al. GPE Discussion Paper Series 10\u201324 (World Health Organization, 2000)."},{"key":"9395_CR19","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.lana.2022.100195","volume":"9","author":"M Mercado-Reyes","year":"2022","unstructured":"Mercado-Reyes, M. et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study. Lancet Reg. Health Am. 9, 100195. https:\/\/doi.org\/10.1016\/j.lana.2022.100195 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"9395_CR20","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.26633\/RPSP.2020.108","volume":"44","author":"LP Borges","year":"2020","unstructured":"Borges, L. P. et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. Pan Am. J. Public Health 44, e108. https:\/\/doi.org\/10.26633\/RPSP.2020.108 (2020).","journal-title":"Pan Am. J. Public Health"},{"key":"9395_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.7326\/M20-3337","volume":"174","author":"Y Fu","year":"2021","unstructured":"Fu, Y. et al. Dynamics and correlation among viral positivity, seroconversion, and disease severity in COVID-19: A retrospective study. Ann. Intern. Med. 174, 453\u2013461. https:\/\/doi.org\/10.7326\/M20-3337 (2021).","journal-title":"Ann. Intern. Med."},{"key":"9395_CR22","doi-asserted-by":"publisher","first-page":"e0008975","DOI":"10.1371\/journal.pntd.0008975","volume":"15","author":"S Duan","year":"2021","unstructured":"Duan, S. et al. Seroprevalence and asymptomatic carrier status of SARS-CoV-2 in Wuhan City and other places of China. PLoS Negl. Trop. Dis. 15, e0008975. https:\/\/doi.org\/10.1371\/journal.pntd.0008975 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"9395_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1473-3099(20)30858-6","volume":"21","author":"H Poustchi","year":"2021","unstructured":"Poustchi, H. et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study. Lancet. Infect. Dis 21, 473\u2013481. https:\/\/doi.org\/10.1016\/S1473-3099(20)30858-6 (2021).","journal-title":"Lancet. Infect. Dis"},{"key":"9395_CR24","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1038\/s41467-020-17703-6","volume":"11","author":"D Simon","year":"2020","unstructured":"Simon, D. et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat. Commun. 11, 3774. https:\/\/doi.org\/10.1038\/s41467-020-17703-6 (2020).","journal-title":"Nat. Commun."},{"key":"9395_CR25","doi-asserted-by":"publisher","first-page":"e0246190","DOI":"10.1371\/journal.pone.0246190","volume":"16","author":"M Fathi","year":"2021","unstructured":"Fathi, M. et al. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS ONE 16, e0246190. https:\/\/doi.org\/10.1371\/journal.pone.0246190 (2021).","journal-title":"PLoS ONE"},{"key":"9395_CR26","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1093\/cid\/ciaa1288","volume":"72","author":"OY Bello-Chavolla","year":"2021","unstructured":"Bello-Chavolla, O. Y. et al. Profiling cases with nonrespiratory symptoms and asymptomatic severe acute respiratory syndrome coronavirus 2 infections in Mexico City. Clin. Infect. Dis. 72, e655\u2013e658. https:\/\/doi.org\/10.1093\/cid\/ciaa1288 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"9395_CR27","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/s41598-021-81629-2","volume":"11","author":"C Jeewandara","year":"2021","unstructured":"Jeewandara, C. et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci. Rep. 11, 2062. https:\/\/doi.org\/10.1038\/s41598-021-81629-2 (2021).","journal-title":"Sci. Rep."},{"key":"9395_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cei.12824","volume":"187","author":"D Frasca","year":"2017","unstructured":"Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. Ageing and obesity similarly impair antibody responses. Clin. Exp. Immunol. 187, 64\u201370. https:\/\/doi.org\/10.1111\/cei.12824 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"9395_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/ijo.2011.208","volume":"36","author":"PA Sheridan","year":"2012","unstructured":"Sheridan, P. A. et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int. J. Obes. 36, 1072\u20131077. https:\/\/doi.org\/10.1038\/ijo.2011.208 (2012).","journal-title":"Int. J. Obes."},{"key":"9395_CR30","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1513\/AnnalsATS.201706-447AW","volume":"14","author":"WD Green","year":"2017","unstructured":"Green, W. D. & Beck, M. A. Obesity impairs the adaptive immune response to influenza virus. Ann. Am. Thorac. Soc. 14, S406\u2013S409. https:\/\/doi.org\/10.1513\/AnnalsATS.201706-447AW (2017).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"9395_CR31","doi-asserted-by":"publisher","first-page":"e0245424","DOI":"10.1371\/journal.pone.0245424","volume":"16","author":"D Frasca","year":"2021","unstructured":"Frasca, D. et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE 16, e0245424. https:\/\/doi.org\/10.1371\/journal.pone.0245424 (2021).","journal-title":"PLoS ONE"},{"key":"9395_CR32","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41422-021-00562-1","volume":"31","author":"S Yu","year":"2021","unstructured":"Yu, S. et al. Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2(pos) subjects. Cell Res. 31, 1148\u20131162. https:\/\/doi.org\/10.1038\/s41422-021-00562-1 (2021).","journal-title":"Cell Res."},{"key":"9395_CR33","doi-asserted-by":"publisher","first-page":"700449","DOI":"10.3389\/fimmu.2021.700449","volume":"12","author":"L Shi","year":"2021","unstructured":"Shi, L. et al. Comparative characterization and risk stratification of asymptomatic and presymptomatic patients with COVID-19. Front. Immunol. 12, 700449. https:\/\/doi.org\/10.3389\/fimmu.2021.700449 (2021).","journal-title":"Front. Immunol."},{"key":"9395_CR34","doi-asserted-by":"publisher","first-page":"e1003358","DOI":"10.1371\/journal.pmed.1003358","volume":"17","author":"J Makaronidis","year":"2020","unstructured":"Makaronidis, J. et al. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and\/or taste in a community-based population in London, UK: An observational cohort study. PLoS Med. 17, e1003358. https:\/\/doi.org\/10.1371\/journal.pmed.1003358 (2020).","journal-title":"PLoS Med."},{"key":"9395_CR35","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1038\/s41467-020-19545-8","volume":"11","author":"S Tosif","year":"2020","unstructured":"Tosif, S. et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat. Commun. 11, 5703. https:\/\/doi.org\/10.1038\/s41467-020-19545-8 (2020).","journal-title":"Nat. Commun."},{"key":"9395_CR36","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/v13112182","volume":"13","author":"A Cedro-Tanda","year":"2021","unstructured":"Cedro-Tanda, A. et al. The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City. Viruses 13, 2182. https:\/\/doi.org\/10.3390\/v13112182 (2021).","journal-title":"Viruses"},{"key":"9395_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/v14030545","volume":"14","author":"A Cedro-Tanda","year":"2022","unstructured":"Cedro-Tanda, A. et al. Early genomic, epidemiological, and clinical description of the SARS-CoV-2 omicron variant in Mexico City. Viruses 14, 545 (2022).","journal-title":"Viruses"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09395-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:44:19Z","timestamp":1669337059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09395-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9395"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09395-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5241"}}